

**The effect of changes in drug utilization on
labor supply and per capita output**

Frank R. Lichtenberg

Columbia University and
National Bureau of Economic Research

Revised March 2002

The effect of changes in drug utilization on labor supply and per capita output

Abstract

Per capita output depends on ability to work and labor supply as well as on output per hour worked. Previous research indicates that R&D-driven technical progress (often embodied technical progress) has been the major source of increase in output per hour worked. Pharmaceuticals are about three times as R&D-intensive as other goods and services. We hypothesize that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person).

We examine the effect of changes in both the average *quantity* and average *vintage* (“quality”) of drugs consumed on labor supply, using longitudinal, condition-level data. First we examine the effect of changes during 1996-1998 in the average number of prescriptions consumed for a condition on the probability of missed work days. The estimates indicate that conditions for which there were above-average increases in utilization of prescriptions tended to have above-average reductions in the probability of missed work days. The estimated value to employers of the reduction in missed work days appears to exceed the employer’s increase in drug cost.

We then examine, using different data, the effect of changes during 1985-1996 in the average *vintage* of prescriptions consumed for a condition on five different, condition-specific measures of activity limitation, including limits on ability to work. The estimates are consistent with the hypothesis that an increase in a condition’s mean drug vintage reduces the probability that people with that condition will experience activity and work limitations, and reduces their average number of restricted-activity days. The estimates imply that activity limitations decline at the rate of about one percent per year of drug vintage, and that the rate of pharmaceutical-embodied technical progress with respect to activity limitations is about 18%. Estimates of the cost of the increase in drug vintage necessary to achieve reductions in activity limitations indicate that increases in drug vintage tend to be very “cost-effective.”

Frank R. Lichtenberg
Columbia University
Graduate School of Business
726 Uris Hall
3022 Broadway
New York, NY 10027

frank.lichtenberg@columbia.edu
phone: (212) 854 4408
fax: (212) 316 9355

Per capita output is the most frequently used indicator of economic prosperity. Per capita output may be viewed as the product of three variables--output per hour worked, hours worked per employed person, and the employment rate:

$$(Y / P) = (Y / H) * (H / E) * (E / P) \quad (1)$$

where:

Y = output
 P = population
 H = hours worked
 E = employment

Hence factors that increase any of the three variables on the right-hand-side of eq. (1) will increase per capita output (Figure 1).¹

In his seminal 1956 paper, Robert Solow showed that technical progress is necessary for there to be sustained growth in output per hour worked (Figure 2). In that paper, Solow assumed that technical progress was exogenous: it descends upon the economy like “manna from heaven,” automatically and regardless of whatever else is going on in the economy (Jones (1998, 32-3)). More recent theoretical (“endogenous growth”) models (Romer (1990)) relaxed this assumption: they have hypothesized that “technical progress is driven by research and development” ((Jones (1998, 89-90)). Empirical evidence (e.g. Griliches and Lichtenberg (1984), Lichtenberg and Siegel (1991)) is consistent with the hypothesis that firms and industries that perform more R&D exhibit higher productivity growth.

Solow and other economists have recognized since the late 1950s that there are two kinds of technical progress: *disembodied* and *embodied*. Suppose that agent *i* in the economy (e.g. a firm or government agency) engages in research and development. If technical progress is disembodied, another agent (*j*) can benefit from agent *i*'s R&D whether or not he purchases agent *i*'s products. But if technical progress is embodied, agent *j* benefits from agent *i*'s R&D only if he purchases agent *i*'s products. Solow

¹ Although they will increase per capita output, increases in the variables on the right-hand-side of eq. (1) will not necessarily increase social welfare. If people prefer being out of the labor force to working, an increase in the employment rate will reduce social welfare. If, on the other hand, people are prevented from working by illness and disability, then innovations that increase employment by enabling people to work will be welfare-enhancing. Such innovations are the focus of this paper.

conjectured that most technical progress was embodied. In one paper (Solow (1962, p. 76)), he assumed that “*all* technological progress needs to be ‘embodied’ in newly produced capital goods before there can be any effect on output.”

A number of econometric studies have investigated the hypothesis that capital equipment employed by U.S. manufacturing firms embodies technological change, i.e. that “each successive vintage of investment is more productive than the last.” Equipment is expected to embody significant technical progress due to the relatively high R&D-intensity of equipment manufacturers. According to the National Science Foundation, the R&D-intensity of machinery and equipment manufacturing is about 50% higher than the R&D-intensity of manufacturing in general, and 78% higher than the R&D intensity of all industries.

These studies have concluded that technical progress embodied in equipment is a major source of manufacturing productivity (output per hour) growth. Hulten (1992) found that as much as 20 percent (and perhaps more) of the BLS total-factor-productivity change (in manufacturing) can be directly associated with embodiment—the higher productivity of new capital than old capital. For equipment used in U.S. manufacturing, best-practice technology may be as much as 23 percent above the average level of technical efficiency. Bahk and Gort (1993) concluded that “Industrywide learning appears to be uniquely related to embodied technical change of physical capital. Once due account is taken of the latter variable, residual industrywide learning [disembodied technical change] disappears as a significant explanatory variable” (p. 579). And Sakellaris and Wilson (2000) estimate that “each vintage is about 12 percent more productive than the previous year’s vintage (in the preferred specification)”, and that equipment-embodied technical change accounted for about two thirds of U.S. manufacturing productivity growth between 1972 and 1996.

In this paper we test the hypothesis that another kind of embodied technical progress—pharmaceutical-embodied technical progress—has increased per capita output via its effect on labor supply (the employment rate and hours worked per employed person; see Figure 3)². The pharmaceutical industry is even more R&D-intensive than

² Rizzo et al (1996) examined the effect of prescribed medicine use on work-loss disability days of currently employed workers only; they did not consider the effect on the probability of being employed.

the equipment industry: according to the NSF, the R&D intensity of drugs and medicines manufacturing is 74% higher than the R&D intensity of machinery and equipment manufacturing (Figure 4). Therefore, it is quite plausible that there is a high rate of pharmaceutical-embodied technical progress.

Data collected in the 1996 National Health Interview Survey indicate that 7% of people between the ages of 18 and 69 are completely unable to work due to illness and disability; another 5% are limited in the kind and amount of the work they can do. Limitations in ability to work place individuals and families at major financial risk: people who are unable to work are more than three times as likely to live below the poverty threshold as people who are not limited, controlling for age, education, race, and sex. As Figure 5 shows, inability to work increases steadily with age: the rate is almost twice as high among 55-64 year-olds (15.2%) as it is among 45-54 year-olds (7.9%).³ This decline in ability to work with respect to age might be interpreted as age-related human capital depreciation. We hypothesize that use of newer drugs increases ability to work (or reduces the rate of human capital depreciation).

At first blush, one might think that employers need only be concerned about work-loss days experienced by currently employed persons. However firms make significant investments in recruitment and training of employees, and if these employees become unable to work, firms are unable to realize returns on these investments. Firms as well as workers incur human capital losses.

We will examine the effect of changes in drug utilization on labor supply using longitudinal, condition-level data in two different ways. The first approach examines the effect of changes in the average *quantity* of drugs (and other medical services) consumed for a given condition, using data from the 1996-1998 waves of the Medical Expenditure Panel Survey (MEPS). The second approach examines the effect of changes in the average *vintage* (FDA approval year) of drugs consumed for a given condition; we hypothesize that drug *quality* tends to increase with vintage. This approach is based primarily on data from National Ambulatory Medical Care Surveys and National Health Interview Surveys during the period 1985-1996. Changes in quantity are positively

³ Since older employed workers tend to earn more than younger employed workers, the percentage reduction in income from inability to work is even greater than the percentage reduction in employment.

correlated across conditions with changes in mean vintage, or quality: there is a significant positive correlation between the percentage increase between 1996 and 1998 in the total number of prescriptions for a condition and the fraction of 1996-1998 prescriptions that were for drugs approved after 1990.⁴

I. The effect of changes in the average quantity of drugs

The 1996-1998 MEPS condition files report condition-specific data for each medical condition reported by each person in each year. It includes the following variables:

- MISSWORK_{ijt} = 1 if one or more missed workdays were associated with condition j borne by person i in year t
= 0 otherwise
- RXNUM_{ijt} = the number of prescribed medicines associated with condition j borne by person i in year t
- OBNUM_{ijt} = the number of office-based events associated with condition j borne by person i in year t
- HSNUM_{ijt} = the number of hospital stays associated with condition j borne by person i in year t

Aggregation of these data up to the condition-year level enables estimation of the following model⁵:

$$\text{MISSWORK}_{.jt} = \beta_{RX} \log(\text{RXNUM}_{.jt}) + \beta_{OB} \log(\text{OBNUM}_{.jt}) + \beta_{HS} \text{HSNUM}_{.jt} + \alpha_j + \delta_t + \varepsilon_{jt} \quad (2)$$

where

- MISSWORK_{.jt} = the fraction of people with condition j in year t who had one or more missed workdays associated with the condition
- RXNUM_{.jt} = the average number of prescribed medicines associated with condition j in year t
- OBNUM_{.jt} = the average number of office-based events associated with condition j

⁴ Based on a sample of 74 2-digit ICD9 conditions, the correlation coefficient is 0.262 (p-value= 0.024). Observations are weighted by the square root of the number of 1996-1998 prescriptions.

⁵ The hypothesis of diminishing marginal productivity of medical services implies that a logarithmic specification is appropriate. Since HSNUM_{.jt} is frequently zero, we do not take the logarithm of this variable.

borne by person i in year t
 $HSNUM_{jt}$ = the average number of hospital stays associated with condition j in year t

Including fixed condition effects (α_j 's) and year effects (δ_t 's) controls for the effect of any determinants of MISSWORK that vary across conditions but not over time and that vary over time but not across conditions.⁶ Estimation of this model will reveal whether conditions for which there were *above-average increases* in utilization of medical services (prescriptions, doctor visits, or hospital stays) tended to have above-average reductions in the fraction of people who had one or more missed workdays associated with the condition.

We restricted the sample to conditions borne by people between the ages of 18 and 65. The micro-level dataset contained 143,536 observations. The aggregated dataset contained about 280 observations (3 years times 93 2-digit ICD9 conditions/year).

Sample mean values of the variables are shown in the following table.

year	misswork	rxnum	obnum	hsnum
1996	0.24	0.99	1.39	0.024
1997	0.20	1.02	1.61	0.034
1998	0.21	1.08	1.72	0.032

With the exception of rxnum, the 1997 figures are much closer to the 1998 figures than they are to the 1996 figures. This may be related to the fact that 1996 was the first year of the survey, so that data for this year may be subject to greater measurement or reporting error than data for the subsequent two years.⁷

The probability that a condition was associated with one or more missed workdays ranged between 20% and 24%. The average number of prescriptions per condition increased by 9% from 1996 to 1998.

We estimated eq. (2) in two ways: probit estimation on grouped data, and weighted least-squares (WLS), weighting by the number of observations in each condition-year cell. Since the dependent variable of eq. (2) is bounded between zero and

⁶ For example, suppose that both the probability of missing work days and the average number of prescriptions vary across regions, and that certain conditions tend to be more prevalent in certain regions. As long as the regional distribution of conditions remains stable over the sample period, fixed-effects estimation controls for the influence of region.

⁷ Since eq. (1) includes fixed year effects, changes in survey reporting and administration whose effects did not vary across conditions will not affect our results.

one, probit estimation is theoretically superior. In practice, the two procedures yielded very similar results.

Weighted least-squares estimates of the key parameters of eq. (2) are shown in the following table:

Parameter	b_{RX}	b_{OB}	b_{HS}
estimate	-0.0414	-0.0049	0.0208
std. error	0.0155	0.0102	0.0623
t-statistic	-2.67	-0.48	0.33
p-value	0.0081	0.6323	0.7384

The estimate of β_{RX} is negative and significantly different from zero, while the estimates of the other two parameters are far from statistically significant. When $\log(\text{obnum})$ and hsnum are dropped from the equation, the estimate (p-value) of β_{RX} is $-.0498$ (0.0033). These estimates are consistent with the hypothesis that *conditions for which there were above-average increases in utilization of prescriptions tended to have above-average reductions in the fraction of people who had one or more missed workdays associated with the condition.*

An increase in the average number of prescriptions consumed for a condition is associated with a reduction in the probability of missing work days due to the condition. Suppose the average number of prescriptions increased by 1 per condition per year. We wish to compare the resulting increase in drug cost to the value of the estimated reduction in missed work days. To a first approximation, the increase in drug cost would simply be the average cost of a prescription, which was \$34.76 in 1996.

We will use the following formula to estimate the value of the reduction in missed work days from a unit increase in the number of prescriptions per condition per year:

$$\begin{aligned}
 V &= (C / H) * (H / D) * E(M | M > 0) * - \frac{d \text{ prob}(M > 0)}{d \text{ RXNUM}} \\
 &= (C / H) * (H / D) * E(M | M > 0) * \text{RXNUM} * - \frac{d \text{ prob}(M > 0)}{d \log(\text{RXNUM})} \\
 &= (C / H) * (H / D) * E(M | M > 0) * \text{RXNUM} * -\beta_{RX} \tag{3}
 \end{aligned}$$

where

- C = employer costs for employee compensation
 H = hours worked
 C / H = employer costs for employee compensation per hour worked
 D = days worked
 H / D = hours worked per day
 M = workdays missed
 E(M | M > 0) = expected number of workdays missed, given that some workdays were missed
prob (M > 0) = probability that some workdays were missed

The sample mean value of RXNUM is 1.03, and our point estimate of $-\beta_{RX}$ is .0498. According to the Bureau of Labor Statistics, in 1996 employer costs for employee compensation per hour worked by civilian workers (C / H) was \$18.68. We assume that hours worked per day (H / D) is 7. The only remaining quantity we need to estimate in order to compute V is E(M | M > 0).⁸

To estimate this, we combined person-level information from the 1996 MEPS Full-Year File with condition-level information from the 1996 MEPS Condition File. The first file provides information about the person's total number of missed work days associated with *all* medical conditions in 1996.⁹ The second file provides information about the number of medical conditions associated with any missed work days in 1996. The following table presents information about people classified by the latter characteristic:

Number of conditions associated with missed work days	Number of people	Mean number of missed work days	Mean number of missed work days per condition
0	4120	0.18	
1	3225	6.88	6.88
2	1476	11.21	5.61
3	660	15.62	5.21
4	250	22.19	5.55
5+	175	28.36	4.59

⁸ Unfortunately the MEPS Condition Files indicate only whether *any* workdays were missed, not the *number* of workdays missed.

⁹ This is the sum of missed workdays in rounds 1, 2, and 3 of the survey (ddnowrk1-ddnowrk3).

There is a strong positive relationship between the number of conditions associated with missed work days and the mean number of missed work days. For example, people with one condition missed 6.70 more work days than people with zero conditions associated with missed work days. We will assume that $E(M | M > 0)$ is a weighted average of the figures in the last column (weighted by the number of people), minus 0.18 (the mean number of missed work days of people with zero missed work-day conditions). Hence $E(M | M > 0) = 6.24 - 0.18 = 6.06$. *The average number of work-days missed per condition per year by people who missed any work days from a condition is 6.06.*

Substituting these figures into eq. (3) yields an estimate of the value of the reduction in missed work days from a unit increase in the number of prescriptions per condition per year:

$$\begin{aligned} V &= (C / H) * (H / D) * E(M | M > 0) * RXNUM * -\beta_{RX} \\ &= \$18.68 * 7 * 6.06 * 1.03 * .0498 \\ &= \$40.64. \end{aligned}$$

A unit increase in the number of prescriptions per condition per year (a .97 increase in $\log(RXNUM)$) would reduce the probability of missing any work days by 5.1%. Since $E(M | M > 0) = 6.06$, it would reduce the expected number of missed work days by 0.31 days, or 2.18 hours. In 1996, the value to employers of this reduction in missed work days would have been \$40.64. This exceeds the average cost of a prescription in 1996 which was \$34.76. Moreover, employers did not bear the entire cost of the prescription. According to the 1997 MEDSTAT MarketScan database, which represents the inpatient and outpatient healthcare service use of individuals nationwide who are covered by the benefit plans of large employers, health plans, and government and public organizations, individuals paid 15 percent of the cost of their drug claims in the form of copayments. Hence the average cost to the employer of an additional prescription may have been $85\% * \$34.76 = \29.66 . The estimated value to employers of the reduction in missed work days appears to exceed the employer's increase in drug cost.

II. The effect of changes in the average vintage of drugs

In section A we will develop an econometric specification for testing the hypothesis that, *ceteris paribus*, the ability of a person with given medical conditions to work is positively related to the vintage(s) of the drug(s) he consumes for those conditions. In section B, we describe the data used to estimate the model. Empirical results are presented in section C.

A. Econometric specification

Consider the following model:

$$L_{ijt} = \beta V_{ijt} + \alpha_j + \delta_t + \gamma Z_{ijt} + \varepsilon_{ijt} \quad (4)$$

where

L_{ijt} = an indicator of the limitations imposed on person i by condition j in year t (80 conditions, $t = 1985, 1989, 1990, \dots, 1996$)

V_{ijt} = an indicator (e.g. the mean) of the vintage of the drugs consumed by person i for condition j in year t

Z_{ijt} = other attributes (e.g. age) of person i with condition j in year t

ε_{ijt} = a disturbance.

This model includes both condition fixed effects (α_j) and year fixed effects (δ_t). Condition fixed effects control for the possibility that some conditions are inherently more limiting than others (independent of drug vintage). Some conditions tend to limit activities much more than others in a given year. For example, only 0.5% of the people who had chronic sinusitis (the second-most prevalent condition in 1990-1992) were limited by it in their major or outside activity, whereas 21.2% of the people who had arthritis (the third-most prevalent condition) were limited by it. Year fixed effects control for the influence of disembodied technical change and for other factors that change over time but do not vary across conditions.

While eq. (4) is a useful starting point, for a number of reasons estimation of this model is neither feasible (due to missing data) nor necessarily appropriate (due to possible nonlinearity and interaction effects). We elaborate on these issues below.

Censoring of vintage data. The vintage data are censored from below: for drugs that have not been approved by the FDA since it was established in 1939, we know only that they are of pre-1939 vintage. One way of addressing the censoring problem is to replace V by a dummy variable (D) defined as follows:

$$\begin{aligned} D &= 1 \text{ if } V > V^* \\ &= 0 \text{ if } V \leq V^*, \end{aligned}$$

where V^* is a vintage threshold ($V^* \geq 1939$). Also define the following:

$$\begin{aligned} V_N &= E(V \mid V > V^*) = \text{mean vintage of "new drugs"} \\ V_O &= E(V \mid V \leq V^*) = \text{mean vintage of "old drugs"} \end{aligned}$$

Due to censoring, only the former is known. But this does not prevent us from testing the hypothesis that users of new drugs are less limited in activity than the users of old drugs, or from estimating the increase in drug cost required to achieve a given reduction in activity limitation.

Suppose we estimate the simple regression of L on D (for simplicity, here we ignore non-vintage determinants of L). The slope of this regression is:

$$b_{LD} = L_N - L_O$$

where

$$\begin{aligned} L_N &= E(L \mid V > V^*) = \text{mean value of } L \text{ for "new drug" users} \\ L_O &= E(L \mid V \leq V^*) = \text{mean value of } L \text{ for "old drug" users} \end{aligned}$$

Hence, if the estimate of b_{LD} is negative and significant, we may reject the null hypothesis that drug vintage has no effect on activity limitations.

One can also estimate the simple regression of drug price (P) on D . The slope of this regression is:

$$b_{PD} = P_N - P_O$$

where

$$P_N = E(P | V > V^*) = \text{mean price of "new drugs"}$$

$$P_O = E(P | V \leq V^*) = \text{mean price of "old drugs"}$$

Hence the ratio of b_{PD} to $-b_{LD}$ is the ratio of the new-vs.-old drug price difference to the new-vs.-old drug reduction in activity limitations, i.e. the increase in drug cost required to achieve a given reduction in activity limitation.

$$\frac{b_{PD}}{-b_{LD}} = \frac{P_N - P_O}{-(L_N - L_O)}$$

In eq. (4), the parameter β is the effect of a *one-year* increase in vintage on L. β is related to b_{LD} as follows:

$$\beta = \frac{\Delta L}{\Delta V} = \frac{(L_N - L_O)}{(V_N - V_O)} = \frac{b_{LD}}{(V_N - V_O)} \quad (5)$$

This implies that, to determine the effect of a one-year increase in vintage on L, one needs to divide the dummy-variable regression coefficient by an estimate of $(V_N - V_O)$.

Potential nonlinearity. If the relationship between L and V is linear, as hypothesized in eq. (4), then the choice of vintage threshold (V^*) won't affect the estimate of β we obtain from eq. (5), e.g. it won't matter whether we define new drugs as post-1970 drugs or post-1980 drugs. However if the relationship is nonlinear—e.g., the reduction in activity limitations from switching from a 1980 to a 1990 drug is greater than the reduction in activity limitations from switching from a 1970 to a 1980 drug—then the choice of V^* will affect the estimate of β . This is illustrated by Figure 6. Suppose that the vintage threshold is increased: V^* shifts to the right. This will increase both V_N and V_O , by different amounts (in general), and will also affect the slope of the straight line passing through the points (V_O, L_O) and (V_N, L_N) . We will therefore estimate the model using several alternative vintage thresholds (1970, 1980, 1985, and 1990), both to check robustness and to investigate the possibility of nonlinearity.

Aggregation. We have data on L, V, and Z, for large samples of individuals over a period of years. However the data on L and V come from different surveys and cover different individuals: data on condition-specific activity limitations come from the National Health Interview Survey—a household survey—and data on condition-specific drug utilization come from the National Ambulatory Medical Care Survey—a provider

(physician) survey. Hence estimation of eq. (4) is not feasible. But by aggregating eq. (4) across individuals, we obtain an equation that can be estimated¹⁰:

$$L_{.jt} = \beta V_{.jt} + \alpha_j + \delta_t + \gamma Z_{.jt} + \varepsilon_{.jt} \quad (6)$$

where

$L_{.jt}$ = is the mean value of L_{ijt} for persons with condition j in year t .

$V_{.jt}$ = is the mean of the vintage indicator of drugs consumed for condition j in year t .

For example, $L_{.jt}$ = is the fraction of people with arthritis in 1996 who are unable to work because of their arthritis, and $V_{.jt}$ is the mean vintage of drugs prescribed to treat arthritis in 1996. If the estimate of β from eq. (6) is negative and significant, that indicates that conditions with greater increases in vintage had greater declines (or smaller increases) in activity limitations.

Interaction effect. In eq. (6), the response of activity limitations to a change in vintage ($\beta = \partial L / \partial V$) is a constant. But it is reasonable to hypothesize that this response is proportional to the average number of drugs consumed by people with that condition:

$$\beta = \beta' N_Rx_j \quad (7)$$

where:

N_Rx_j is the average annual number of prescriptions consumed for condition j by people with that condition.

Substituting eq. (7) into eq. (6),

$$L_{.jt} = \beta' (N_Rx_j * V_{.jt}) + \alpha_j + \delta_t + \gamma Z_{.jt} + \varepsilon_{.jt} \quad (8)$$

Due to censoring of vintage data discussed earlier, the best way to measure V given the available data is as the ratio of the number of new (e.g. post-1980) drugs prescribed for

¹⁰ Estimation based on aggregate data may have advantages over estimation based on individual-level data. Suppose that the disturbance of eq. (2) is correlated with vintage, due to unobserved heterogeneity: people with more severe cases of a given condition may tend to take newer (or older) drugs for that condition. In this case, the estimate of β from eq. (2) will be biased. But as long as the exogenous change in condition mean unobserved severity is uncorrelated with the change in mean vintage, the estimate of β from eq. (4) will be unbiased.

the condition to the total number of drugs prescribed for the condition. Since N_{Rx} is the ratio of the total number of drugs prescribed for the condition to the number of people with the condition, $(N_{Rx} * V)$ equals the *number of new drugs prescribed for the condition per person with the condition*. For example, if $(N_{Rx} * V) = 1$ in 1996, that means that, on average, people with the condition are taking one new drug for that condition.

Now consider the costs and benefits of a unit increase in $(N_{Rx} * V)$. A possible estimate of this cost is the average cost of a prescription for a new drug. NAMCS does not contain any information about drug costs, but according to the 1997 MEPS, the average cost of a prescription for a post-1980 drug in 1997 was \$59.08. If use of the new drug did not reduce use of old drugs, this would be a reasonable estimate of the cost of a unit increase in $(N_{Rx} * V)$. However in reality, use of new drugs is likely to reduce use of old drugs (Lichtenberg and Philipson (2002)). If there were 1-for-1 substitution of new for old drugs, the cost of the unit increase in $(N_{Rx} * V)$ would be the *difference* between the price of the new drug and the price of the old drug. The average cost of a prescription for a pre-1980 drug in 1997 was \$26.66, so this price difference is \$32.42.

The *benefit*, in dollar terms, of a unit increase in $(N_{Rx} * V)$ is the reduction in the probability of experiencing the limitation ($-\beta'$) times the value of, or willingness to pay for, freedom from the limitation (WTP). Suppose, for example, that consuming one new drug (increasing $(N_{Rx} * V)$ by 1) reduces the probability of being unable to work by .03 (from 8% to 5%). If the value of being able to work is \$35,000—about the average annual earnings of American workers—then the benefit of reducing this activity limitation is $(-\beta') * WTP = .03 * \$35,000 = \$1050$. If the benefit of the increase in drug vintage exceeds its cost, the increase in vintage raises social welfare.

B. Data

1. Limitations of activity, by condition and year

Numerous health surveys (e.g., the Medical Expenditure Panel Survey) collect data on respondents' activity limitations, including limitation in ability to work. But people with activity limitations often suffer from multiple conditions, and these surveys

do not indicate *which* conditions are responsible for their activity limitations¹¹. The National Health Interview Survey is the only survey we are aware of that collects *condition-specific* activity limitation data.

The purpose of the National Health Interview Survey (NHIS) is to obtain information about the amount and distribution of illness, its effects in terms of disability and chronic impairments, and the kinds of health services people receive.

Condition—Condition is a general term that includes any specific illness, injury, or impairment. Condition data are derived from the survey in two ways. First, respondents are asked to identify any conditions that caused certain types of impact associated with health, such as a visit to a doctor or a day spent in bed. Second, respondents are read lists of selected chronic conditions and asked whether they or any family members have any of these conditions. The latter information is used in making prevalence estimates. At a later point in the survey, a series of questions is asked about each of the conditions identified in either of the two ways just described. The information obtained on each condition helps to clarify the nature of the condition and whether medical services have been involved in its diagnosis or treatment. It also aids in the coding of the condition. All conditions except impairments are coded according to the ninth revision of the *International Classification of Diseases (5)* with certain modifications adopted to make the codes more suitable for information derived from a household survey.

Chronic condition—A condition is considered chronic if the respondent indicates it was first noticed more than 3 months before the reference date of the interview, or it is a type of condition that ordinarily has a duration of more than 3 months. Examples of conditions that are considered chronic regardless of their time of onset are diabetes, heart conditions, emphysema, and arthritis.¹²

¹¹ 1996 MEPS data indicate that among people with at least one medical condition, 79% had 2 or more conditions, 60% had 3 or more, and 31% had five or more. Moreover 95% of conditions are borne by people with 2 or more conditions, 60% of conditions are borne by people with 5 or more conditions, and 18% of conditions are borne by people with 10 or more conditions.

¹² The majority of conditions reported in the condition file are chronic conditions. For example, 86% of conditions reported in 1996 were chronic conditions.

Limitation of activity because of chronic conditions— Persons are classified in terms of the major activity usually associated with their particular age group. The major activities for the age groups are:

1. Ordinary play for children under 5 years of age
2. Attending school for those 5–17 years of age
3. Working or keeping house for persons 18–69 years of age
4. Capacity for independent living (for example, the ability to bathe, shop, dress, eat, and so forth, without needing the help of another person) for those 70 years of age and over

People 18–69 years of age who are classified as keeping house are also classified by their ability to work at a job or business. (In Collins (1997), the major activity of persons 65–69 years is assumed to be working or keeping house; however, questions were also asked about the capacity for independent living in this age group, which would permit an alternative definition of limitation.)

In regard to these activities, each person is classified into one of four categories:

1. Unable to perform the major activity
2. Able to perform the major activity but limited in the kind or amount of this activity
3. Not limited in the major activity but limited in the kind or amount of other activities
4. Not limited in any way

In regard to these four categories, NHIS publications often classify persons only by whether they are limited (groups 1–3) or not limited (group 4). Persons are not classified as limited in activity unless one or more chronic conditions are reported as the cause of the activity limitation. If more than one condition is reported, the respondent is asked to identify the condition that is the major cause of the limitation.

Condition Record File—This file contains information for each reported health condition. NHIS condition records can be used to calculate aggregate estimates and rates of the incidence of acute conditions, prevalence of selected chronic conditions, disability days and utilization associated with acute or chronic conditions, and chronic conditions causing limitation of activity. The Condition file contains the following types of records:

1. Condition records, either acute or chronic, which are associated with disability days, doctor visits and/or hospitalizations in the two weeks preceding the interview.

2. Chronic condition records when the condition is reported to be the main or secondary cause of activity limitation or limitation in ability to work.
3. Chronic condition records reported in response to a checklist of conditions for each body system, e.g., digestive. The total sample was divided into six sub-samples. Each sub-sample was asked the set of conditions corresponding to one of the six chronic disease checklists.

To calculate limitation of activity due to chronic conditions on a condition basis, NCHS (1996, p. 51) says that all chronic condition records, not just those reported in response to a checklist of conditions for each body system, should be used.

2. Vintage distribution of drugs utilized, by condition and year

National Ambulatory Medical Care Surveys offer information on patients' visits to a national sample of office-based physicians. The surveys collect information on all drugs/medications ordered, administered, or provided during office visits. The data items include medication code, generic name and code, brand name, entry status, prescription status, federal controlled substance status, composition status, and related ingredient codes. Also included are demographic items describing the patient, such as age, sex, race, and ethnicity. The universe consists of office visits to nonfederally employed physicians classified by the American Medical Association (AMA) or the American Osteopathic Association (AOA) as "office-based, patient care" (excluding specialties of anesthesiology, pathology, and radiology), from 112 Primary Sampling Units (PSUs) in the United States.

Each NAMCS office visit record reports the physician's diagnoses, any drugs prescribed (including the names of each of the ingredients of combination drugs), and a sampling weight.¹³ Hence one can calculate, for each year in which NAMCS was conducted, the joint distribution of prescribed medicines, by drug and diagnosis¹⁴.

To determine the vintages (FDA approval dates) of drugs reported in NAMCS, we used two unpublished files obtained from the FDA. The first is a list of all of the 821

¹³ About 10% of NAMCS drug mentions are nonprescription drugs; about 18% are combination drugs. Exclusion of nonprescription and combination drugs has very little effect on our estimates.

¹⁴ Up to three diagnoses may be recorded, but usually only one is recorded. When multiple diagnoses are recorded, we allocate the drugs prescribed equally across the diagnoses.

new molecular entities (NMEs) approved during the period 1950-1993. The second is a list of all new drug applications (NDAs) approved during the period 1939-1998. (The first FDA drug approval occurred in 1939.) This list includes both new molecular entities approved and other NDAs approved (new formulations, new manufacturers, etc.). Although the two lists are broadly consistent, there are some discrepancies. Figure 7 shows the number of new molecular entities approved per year, as computed from both lists.¹⁵ We consider the first list to be more reliable for the 1950-1993 period, since the FDA constructed it for the specific purpose of identifying NMEs approved during the period. We use the second list only to provide data on NMEs approved during 1939-1949 and 1994-1998. We matched NAMCS generic drug names to ingredient names contained in FDA new molecular entity approvals.

Some drugs existed before the FDA was established in 1939. The vintages of these drugs are unknown—it is only known that they are of pre-1939 vintage. In 1980—the first year in which NAMCS collected drug data—about 60% of prescriptions were for drugs of pre-1939 vintage. By 1998, this fraction had declined to about 40%.¹⁶

To obtain meaningful indicators of the vintage distribution of drugs by condition and year, we must address the problem posed by the censoring of this distribution. There are two ways to do this. One is to impute a (reasonable) vintage value for drugs of unknown (pre-1939) vintage. This allows estimation of the mean vintage of all prescriptions, including those of unknown vintage. Figure 8 shows the mean vintage of prescriptions, by year, when the value 1900 is imputed to drugs with missing vintages. When this imputation is used, the mean age (= year prescribed – vintage) of drugs is fairly stable, but declines slightly, from about 55 years during 1980-85 to about 52 years during 1989-98.

A second approach is to use indicators such as those shown in Figure 9, i.e. the fraction of drugs prescribed for condition j in year t of vintage greater than v_0 (e.g. $v_0 =$

¹⁵ We also merged the two lists, by new drug approval number, and calculated the difference in approval years recorded in the two lists. The mean and median differences were both approximately zero, and 98% of the differences were between -2 and $+2$ years, but there were 5 cases in which the absolute difference exceeded 10 years.

¹⁶ These figures treat a prescription for a combination drug—a drug with multiple ingredients—as a prescription for each ingredient. For example, a prescription for a drug containing the two ingredients benzalkonium chloride and tyloxapal is treated as two prescriptions, one for each ingredient.

1970, 1980, and 1990). The fraction of prescriptions that were for drugs approved after 1970 increased from 7.8% in 1980 to 31.2% in 1990, and to 40.3% in 1998. We will try both of these approaches.

Table 1 lists the 25 most frequent generic substances in drug mentions at office visits in 1993. The top 25 ingredients accounted for 30.0 percent of all drug mentions.

As Figure 10 shows, there is considerable variation across conditions with respect to the rate of change in the drug vintage distribution. The Figure shows the percent of 1998 prescriptions that were for drugs approved by the FDA after 1980, by condition, for conditions with more than 20 million prescriptions in 1998. About half of the drugs used for three major conditions—DISEASES OF OTHER ENDOCRINE GLANDS, HYPERTENSIVE DISEASE, and NEUROTIC DISORDERS, PERSONALITY DISORDERS, AND OTHER NONPSYCHOTIC MENTAL DISORDERS—were post-1980 drugs. In contrast, only one-sixth of the drugs used for three other major conditions—ACUTE RESPIRATORY INFECTIONS, DISEASES OF THE EAR AND MASTOID PROCESS, and OTHER DISORDERS OF FEMALE GENITAL TRACT—were post-1980 drugs. We will rely on this (presumably exogenous) cross-condition variation in the change in the vintage distribution to identify the effect of vintage on activity limitations.

3. Average annual number of prescriptions consumed, by condition

The average annual number of prescriptions consumed, by condition (N_{Rx_j} in eq. (8)), can be calculated for two different years during our 1985-1996 sample period from the medical conditions files of two household surveys: the 1987 National Medical Expenditure Survey and the 1996 Medical Expenditure Panel Survey. Each of these files contains about 75,000 condition records. We calculated the mean number of prescriptions consumed, by (2-digit ICD9) condition, in each year; N_{Rx_j} is the mean of the 1987 and 1996 condition- j means.¹⁷

¹⁷ The average number of prescriptions per condition was 1.22 in 1987 and 1.04 in 1996.

4. Prescription prices and vintages

Estimation of price differences between new and old drugs requires data on the prices and vintages of a cross-section of prescriptions. We obtained data on prescription prices from the 1997 MEPS Prescribed Medicines file, which contains price data for 234,473 prescriptions, coded by National Drug Code number. Using Multum's denorm table, we determined the names of the active ingredients contained in each of these prescriptions. To determine vintages of these prescriptions, we matched these ingredient names to the ingredient names contained in FDA new molecular entity approvals (described above).

C. Empirical results

We estimated eq. (8) for five different measures of the (dependent) activity limitation variable (L), and using five alternative definitions of the vintage variable (V). The activity limitation variables are:

main_act_limit = number of people with condition whose *major activity* is limited, mainly due to this condition, as % of total number of people with condition

main_work_limit = number of people with condition whose *ability to work* is limited, *mainly* due to this condition, as % of total number of people with condition

any_work_limit = number of people with condition whose *ability to work* is limited, *mainly or secondarily* due to this condition, as % of total number of people with condition

unable_work = number of people with condition who are *unable to work*, *mainly* due to this condition, as % of total number of people with condition

restricted_days = mean number of restricted activity days due to this condition in the two weeks preceding the interview

The five alternative definitions of the vintage variable are¹⁸:

V_Mean = mean vintage of drugs consumed by people with the condition (setting the vintage of drugs of missing vintage to 1900)

¹⁸ Each of these variables is multiplied by mean number of prescriptions consumed for the condition.

POST70 = number of post-1970 drugs consumed by people with the condition as % of total number of drugs consumed by people with the condition

POST80 = number of post-1980 drugs consumed by people with the condition as % of total number of drugs consumed by people with the condition

POST85 = number of post-1985 drugs consumed by people with the condition as % of total number of drugs consumed by people with the condition

POST90 = number of post-1990 drugs consumed by people with the condition as % of total number of drugs consumed by people with the condition

The sample includes chronic conditions experienced by people between the ages of 18 and 69 in the years 1985 and 1989-1996.¹⁹ The micro-level data set contains about 320,000 observations. The data were aggregated by 2-digit ICD9 code and year; the aggregate data set contains about 630 observations (9 years * about 70 conditions). The model was estimated using weighted least squares (WLS), with the weight equal to the number of sample conditions in that condition-year cell.²⁰ All models include the following covariates: condition fixed effects, year fixed effects, mean age, mean years of schooling, percent male, and percent white.

The estimates are presented in Table 2. Estimates in the first column are based on the first vintage measure, mean vintage of drugs consumed for the condition. The coefficients on this measure are negative and highly significant for four of the five dependent variables (all except `unable_work`). This is consistent with the hypothesis that *an increase in a condition's mean drug vintage reduces the probability that people with that condition will experience activity and work limitations, and reduces their average number of restricted-activity days.*

Estimates in the second column are based on the “new drug share”, using the lowest vintage threshold (1970). Not surprisingly (due to potentially erroneous

¹⁹ The NHIS collected consistent data on chronic conditions from 1982 to 1996 (major changes were made to the survey in 1997), but NAMCS was not conducted in 1982-1984 and in 1986-1988. It has been conducted annually since 1989.

²⁰ Since most of the dependent variables are bounded between zero and one, we also computed probit estimates of some models. The results were very consistent with the WLS estimates: the probit t-statistics on the vintage coefficient were generally about 20% smaller than the WLS t-statistics, but probit p-values were also generally < .001. Since WLS coefficients are easier to interpret than probit coefficients, we report WLS estimates.

missing-value imputations in the first measure), this variable is more strongly (inversely) related to all of the activity limitation measures than mean vintage is: all of the t-statistics are higher in column 2 than they are in column 1. All of the dependent variables are negatively and significantly (at the .02 or lower level) related to POST70.²¹

The remaining three columns are also based on the “new drug share” measure of vintage, but use increasing vintage thresholds (1980, 1985, and 1990). With only one exception (the POST90 coefficient in the restricted_days regression), all of the vintage coefficients are negative and highly statistically significant. Thus, *the finding of a significant negative effect of drug vintage on activity limitations appears to be quite robust to alternative vintage measures and definitions of activity limitations.*

Recall that the vintage coefficients in columns 2 through 5 in Table 2 should be interpreted as new-drug vs. old-drug differences in mean limitations ($L_N - L_O$), and that to determine the effect of a *one-year* increase in vintage on L, one needs to divide these coefficients by an estimate of ($V_N - V_O$). Vintages of pre-1939 drugs are unknown, but if we exclude pre-1939 drugs—and redefine old drugs as drugs for which ($1939 \leq \text{vintage} \leq V^*$)—we can calculate $(L_N - L_O)/(V_N - V_O)$.²² To determine the *percentage* effect on L of a *one-year* increase in vintage, we divide this ratio by the mean value of L. Estimated percentage reductions in activity limitations from a one-year increase in vintage (based on $V^* = 1985$) are:

main_act_limit	1.0%
main_work_limit	1.1%
any_work_limit	0.8%
unable_work	1.2%
restricted_days	1.0%

These estimates imply that *activity limitations decline at the rate of about one percent per year of drug vintage.* Previous authors have argued that the annual rate of embodied

²¹ NHIS collects data on subcategories of restricted activity days, i.e. work-loss days and bed-days. Vintage coefficients were never significant in regressions of these more detailed measures.

²² We calculate this by including *two* vintage variables in the model, e.g. POST39—the number of post-1939 drugs consumed by people with the condition as % of total number of drugs consumed by people with the condition—and POST85, and dividing the POST85 coefficient by the difference between the mean vintage of 1939-1985 drugs (=1968) and the mean vintage of post-1985 drugs (=1989). (In these regressions, the POST39 coefficient is never statistically significant.)

technical progress should be measured as the percentage change in output from a one-year increase in the vintage of an input divided by the input's share in total cost of production. CMS data indicate that during the period 1985-1996, the average share of prescription drug expenditure in national health expenditure was 5.6%. This implies that *the rate of pharmaceutical-embodied technical progress with respect to activity limitations was about 18%.*²³

As discussed above, by combining these estimates with data on the average prices of new and old drugs, we can estimate the cost of the increase in drug vintage necessary to achieve reductions in activity limitations. If use of a new drug does not reduce use of old drugs, the cost of a unit increase in $(N_Rx * V)$ is P_N . If, on the other hand, there is 1-for-1 substitution of new for old drugs, the cost of the unit increase in $(N_Rx * V)$ would be the *difference* between the price of the new drug and the price of the old drug $(P_N - P_O)$. For convenience, we refer to these as upper- and lower-bound estimates, respectively, of the cost of a unit increase in $(N_Rx * V)$. To estimate cost per unit reduction in an activity limitations variable, we divide either P_N or $(P_N - P_O)$ by minus the vintage coefficient.

These calculations are shown in Table 3. Because the dependent variable in the `restricted_days` regression was the mean number of restricted activity days due to this condition in just the two weeks preceding the interview, we “annualized” these coefficients by expressing them as percentages of average 2-week restricted activity days (i.e., we divided by $.838 = \text{mean}(\text{restricted_days})$), and then multiplied by average annual restricted activity days per person due to chronic conditions (8.3 days). The annualized coefficients are about ten times as large in magnitude as the original (2-week) coefficients.

The last column of Table 3 shows the average (across the 4 vintage thresholds) estimate of the vintage cost of reduced activity limitations. The “upper bound” average estimate of the vintage cost of enabling a person to work (`unable_work`) is \$2570; the “lower bound” average estimate is just over half as much (\$1357). The average annual earnings of a full-time year-round American worker are currently in the neighborhood of

²³ As noted above, Sakellaris and Wilson (2000) estimate that “each vintage [of manufacturing equipment] is about 12 percent more productive than the previous year’s vintage (in the preferred specification).”

\$35,000. Hence the increase in vintage would be “cost-effective,” even if the earnings of the person enabled to work were a small fraction (e.g. 10%) of average earnings. Costs of *reducing* work limitations and activity limitations in general are about half as great as the cost of shifting the person from completely unable to work to able to work.

The upper- and lower-bound estimates of the cost of achieving one less restricted-activity day are \$34 and \$18, respectively. Average daily employee compensation is currently about \$140, about four times the upper-bound estimate. Though smaller than the other ratio of benefit to cost, the vintage-induced reduction in restricted activity days also appears to be highly “cost-effective.”

Finally, notice that the vintage cost of reducing activity limitations generally declines as the vintage threshold (V^*) increases. While these differences may not be statistically significant, they suggest that the relationship between vintage and activity limitations may be nonlinear—e.g., that the reduction in activity limitations from switching from a 1980 to a 1990 drug was greater than the reduction in activity limitations from switching from a 1970 to a 1980 drug.

III. Summary and Conclusions

Per capita output depends on ability to work and labor supply as well as on output per hour worked. Previous research indicates that R&D-driven technical progress (often embodied technical progress) has been the major source of increase in output per hour worked. Pharmaceuticals are about three times as R&D-intensive as other goods and services. We hypothesized that pharmaceutical-embodied technical progress increases per capita output via its effect on labor supply (the employment rate and hours worked per employed person). If this is the case, the ability of a person with given medical conditions to work is positively related to the vintage of the drug(s) he consumes for those conditions, *ceteris paribus*. Since inability to work increases steadily with age, an alternative way of stating this hypothesis is that use of newer drugs reduces the rate of human capital depreciation.

First we examined the effect of changes during 1996-1998 in the average *number* of prescriptions consumed for a condition on the probability of missed work days. The

estimates indicated that conditions for which there were above-average increases in utilization of prescriptions tended to have above-average reductions in the probability of missed work days. The estimated value to employers of the reduction in missed work days appears to exceed the employer's increase in drug cost.

We then examined, using different data, the effect of changes during 1985-1996 in the average *vintage* of prescriptions consumed for a condition on five different, condition-specific measures of activity limitation, including limits on ability to work. There was considerable variation across conditions with respect to the rate of change in the drug vintage distribution; we relied on this to identify the effect of vintage on activity limitations.

The estimates were consistent with the hypothesis that an increase in a condition's mean drug vintage reduces the probability that people with that condition will experience activity and work limitations, and reduces their average number of restricted-activity days. The finding of a significant negative effect of drug vintage on activity limitations appeared to be quite robust to alternative vintage measures and definitions of activity limitations. The estimates implied that activity limitations decline at the rate of about one percent per year of drug vintage, and that the rate of pharmaceutical-embodied technical progress with respect to activity limitations is about 18%.

By combining these estimates with data on the average prices of new and old drugs, we estimated the cost of the increase in drug vintage necessary to achieve reductions in activity limitations. We calculated both "upper-bound" estimates—which assume that use of a new drug does not reduce use of old drugs—and "lower-bound estimates"—which assume that there is 1-for-1 substitution of new for old drugs.

The "upper bound" average estimate of the vintage cost of enabling a person to work is \$2570; the "lower bound" average estimate is just over half as much (\$1357). Since the average annual earnings of a full-time year-round American worker is about \$35,000, the increase in vintage would be "cost-effective," even if the earnings of the person enabled to work were a small fraction (e.g. 10%) of average earnings. Costs of reducing work limitations and activity limitations in general are about half as great as the cost of shifting the person from completely unable to work to able to work.

The upper- and lower-bound estimates of the cost of achieving one less restricted-activity day are \$34 and \$18, respectively. Average daily employee compensation is currently about \$140, about four times the upper-bound estimate. Though smaller than the other ratio of benefit to cost, the vintage-induced reduction in restricted activity days also appears to be highly “cost-effective.”

The evidence suggests that the relationship between vintage and activity limitations may be nonlinear—e.g., that the reduction in activity limitations from switching from a 1980 to a 1990 drug was greater than the reduction in activity limitations from switching from a 1970 to a 1980 drug.

References

- Bahk, Byong-Hyong and Michael Gort (1993), "Decomposing Learning by Doing in New Plants", *Journal of Political Economy*, 101, 561-583.
- Collins, J. G. (1997), *Prevalence of selected chronic conditions: United States, 1990-1992*. National Center for Health Statistics. *Vital Health Stat* 10(194).
- Griliches, Zvi, and Frank Lichtenberg (1984), "R&D and Productivity at the Industry Level: Is There Still a Relationship?," in *R&D, Patents, and Productivity*, Zvi Griliches, ed. (Chicago: Univ. of Chicago Press).
- Hulten, Charles R., "Growth Accounting When Technical Change is Embodied in Capital," *The American Economic Review*, Vol. 82, No. 4. (Sep., 1992), pp. 964-980.
- Jones, Charles I. (1998), *Introduction to Economic Growth* (New York: Norton).
- Lichtenberg, Frank, and Tomas Philipson (2001), "The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry," working paper, December.
- Lichtenberg, Frank, and Donald Siegel (1991), "The Impact of R&D Investment on Productivity: New Evidence Using Linked R&D-LRD Data," with Donald Siegel, *Economic Inquiry* 29 (April), 203-28.
- Nelson C, Woodwell D. (1998), *National Ambulatory Medical Care Survey: 1993 Summary*. National Center for Health Statistics. *Vital Health Stat* 13(136).
- National Center for Health Statistics (1999), *National Health Interview Survey, 1996: Codebook and Questionnaires*, First ICPSR Version, April 1999, Inter-university Consortium for Political and Social Research, Ann Arbor, Michigan.
- Rizzo, J., T. Abbott, and S. Pashko, "Labour Productivity Effects of Prescribed Medicines for Chronically Ill Workers," *Health Economics*, vol. 5: 249-265 (1996).
- Sakellaris, Plutarchos and Dan Wilson (2000), "The Production-Side Approach to Estimating Embodied Technological Change," mimeo.
- Solow, Robert M. (1956), "A Contribution to the Theory of Economic Growth," *Quarterly Journal of Economics* 70 (February), 65-94.
- (1962), "Technical Progress, Capital Formation, and Economic Growth," *The American Economic Review*, Vol. 52, No. 2, Papers and Proceedings of the Seventy-Fourth Annual Meeting of the American Economic Association. May, pp. 76-86.

Figure 1
Determinants of per capita output




Figure 2

Existing evidence on the contribution of technical progress to growth in per capita output




Figure 3

Hypothesized additional contribution of technical progress to growth in per capita output






Figure 4
Industrial R&D funds as a percent of net sales in R&D-performing companies, 1997



Source: National Science Foundation.

Figure 5
Percent of people unable to work, by age



The figures are based on pooled data from 1987-1996 National Health Interview Surveys.

Figure 6
Potential nonlinearity in the relationship between
drug vintage (V) and activity limitations (L)






Figure 7
Alternative estimates of the number of new molecular entities
approved by the FDA, by year, 1939-1998



Source: unpublished FDA data.

Figure 8
Mean vintage of drugs prescribed, 1980-1998



Note: vintage of (pre-1939) drugs with unknown vintages is assumed to be 1900.

Figure 9
Fraction of prescriptions that were for drugs
approved after given dates, by year, 1980-1998




Table 1
 Number of occurrences and percent of all drug mentions by the 25 most frequent generic substances in drug mentions at office visits: United States, 1993

Generic substance	Number of occurrences, in thousands ^{1,2}	Percent of all drug mentions
All generic substances	1,080,968	100.0%
Amoxicillin	35,234	3.3%
Acetaminophen	34,277	3.2%
Hydrochlorothiazide	15,217	1.4%
Albuterol	14,943	1.4%
Ibuprofen	14,405	1.3%
Multivitamins general	14,064	1.3%
Erythromycin	13,459	1.2%
Aspirin	13,293	1.2%
Phenylephrine	12,568	1.2%
Guaifenesin	11,727	1.1%
Estrogens	11,660	1.1%
Furosemide	11,212	1.0%
Prednisone	10,833	1.0%
Codeine	10,153	0.9%
Digoxin	9,964	0.9%
Trimethoprim	9,886	0.9%
Diltiazem	9,541	0.9%
Hydrocortisone	9,516	0.9%
Phenylpropanolamine	9,485	0.9%
Rantidine	9,325	0.9%
Sulfamethoxazole	9,233	0.9%
Beclomethasone	8,871	0.8%
Insulin	8,720	0.8%
Naproxen	8,555	0.8%
Enalapril	8,416	0.8%

1 Frequency of mention combines single-ingredient agents with mentions of the agent as an ingredient in a combination drug.

2 Based on an estimated 913,503,000 drug mentions in 1993.

Source: Nelson C, Woodwell D. National Ambulatory Medical Care Survey: 1993 Summary. National Center for Health Statistics. Vital Health Stat 13(136). 1998, Table 34.




Figure 10
Percent of 1998 prescriptions that were for drugs approved by the FDA after 1980, by condition (conditions with more than 20 million prescriptions)

Table 2
 Estimates of vintage coefficients from eq. (6):
 alternative measures of activity limitation and drug vintage

Column:	1	2	3	4	5
Vintage measure:	V_Mean	post70	post80	post85	post90

Dependent variable: main act limit (mean = 0.198)

vintage coefficient	-0.00053	-0.03796	-0.03492	-0.05968	-0.07747
std. err.	0.00018	0.00885	0.00831	0.0136	0.02029
t-stat	-3.03	-4.29	-4.2	-4.39	-3.82
p-value	0.0026	<.0001	<.0001	<.0001	0.0001

Dependent variable: main work limit (mean = 0.152)

vintage coefficient	-0.00038	-0.03129	-0.02904	-0.05094	-0.06498
std. err.	0.00016	0.00833	0.00782	0.01279	0.01907
t-stat	-2.32	-3.76	-3.71	-3.98	-3.41
p-value	0.0206	0.0002	0.0002	<.0001	0.0007

Dependent variable: any work limit (mean = 0.258)

vintage coefficient	-0.00054	-0.03534	-0.0367	-0.0625	-0.05934
std. err.	0.00018	0.00914	0.00855	0.01398	0.021
t-stat	-3.01	-3.87	-4.29	-4.47	-2.83
p-value	0.0028	0.0001	<.0001	<.0001	0.0049

Dependent variable: unable work (mean = 0.095)

vintage coefficient	-0.00016	-0.01647	-0.01546	-0.03401	-0.04806
std. err.	0.00013	0.00665	0.00624	0.01018	0.01513
t-stat	-1.23	-2.48	-2.48	-3.34	-3.18
p-value	0.2203	0.0135	0.0135	0.0009	0.0016

Dependent variable: restricted days (mean = 0.838)

vintage coefficient	-0.00328	-0.17585	-0.13504	-0.25134	-0.17854
std. err.	0.00136	0.06938	0.06523	0.10674	0.1592
t-stat	-2.41	-2.53	-2.07	-2.35	-1.12
p-value	0.0163	0.0115	0.0389	0.0189	0.2626

Table 3

Estimated costs of increase in vintage necessary to achieve reductions in activity limitations

Column:	1	2	3	4	5
Vintage threshold:	1970	1980	1985	1990	average

Drug prices

P_N	\$52.35	\$59.08	\$65.54	\$65.15
P_O	\$26.09	\$26.66	\$29.61	\$32.38
$P_N - P_O$	\$26.26	\$32.42	\$35.92	\$32.76

vintage coefficients

main_act_limit	-0.038	-0.035	-0.060	-0.077
main_work_limit	-0.031	-0.029	-0.051	-0.065
any_work_limit	-0.035	-0.037	-0.062	-0.059
unable_work	-0.016	-0.015	-0.034	-0.048
restricted_days (annualized)	-1.742	-1.337	-2.489	-1.768

"Upper-bound cost estimates": $P_N / -(vintage\ coefficient)$

main_act_limit	\$1,379	\$1,692	\$1,098	\$841	\$1,252
main_work_limit	\$1,673	\$2,034	\$1,287	\$1,003	\$1,499
any_work_limit	\$1,481	\$1,610	\$1,049	\$1,098	\$1,309
unable_work	\$3,178	\$3,820	\$1,927	\$1,356	\$2,570
restricted_days (annualized)	\$30	\$44	\$26	\$37	\$34

"Lower-bound cost estimates": $(P_N - P_O) / -(vintage\ coefficient)$

main_act_limit	\$692	\$928	\$602	\$423	\$661
main_work_limit	\$839	\$1,116	\$705	\$504	\$791
any_work_limit	\$743	\$883	\$575	\$552	\$688
unable_work	\$1,594	\$2,096	\$1,056	\$682	\$1,357
restricted_days (annualized)	\$15	\$24	\$14	\$19	\$18